Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Non Operating Investment Income (2020 - 2025)

Roivant Sciences (ROIV) has disclosed Non Operating Investment Income for 6 consecutive years, with $21.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Investment Income rose 201.3% year-over-year to $21.6 million, compared with a TTM value of $109.7 million through Dec 2025, up 244.61%, and an annual FY2025 reading of $55.2 million, up 215.04% over the prior year.
  • Non Operating Investment Income was $21.6 million for Q4 2025 at Roivant Sciences, down from $128.5 million in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $128.5 million in Q3 2025 and bottomed at -$54.7 million in Q3 2022.
  • Average Non Operating Investment Income over 5 years is $3.7 million, with a median of -$8.6 million recorded in 2021.
  • The sharpest move saw Non Operating Investment Income skyrocketed 301.3% in 2024, then plummeted 225.61% in 2025.
  • Year by year, Non Operating Investment Income stood at -$8.6 million in 2021, then surged by 401.06% to $25.9 million in 2022, then crashed by 140.34% to -$10.5 million in 2023, then crashed by 103.63% to -$21.3 million in 2024, then surged by 201.3% to $21.6 million in 2025.
  • Business Quant data shows Non Operating Investment Income for ROIV at $21.6 million in Q4 2025, $128.5 million in Q3 2025, and -$19.1 million in Q2 2025.